BioSpace News Archive

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it has completed enrollment of 60 NASH stage 3 (“F3”) subjects in the Phase 2 ALTITUDE-NASH clinical trial.

Panavance Therapeutics Inc. announced that Greg Bosch, Chairman and CEO of Panavance Therapeutics along with other members of the Panavance Leadership Team will participate in the Virtual Investor Innovations in Oncology Spotlight Event on Wednesday, December 7, 2022 at 2:00 PM ET.

Agendia, Inc., a leader in gene expression profiling for early-stage breast cancer, received acceptance for all six abstract submissions that will help guide the future of personalized cancer care and will be presented at the 2022 San Antonio Breast Cancer Symposium (SABCS).

STEMTECH CORPORATION announces that Darryl V. Green, Board Director, Investor and Advisor, will be participating at the RHK Capital Disruptive Growth Conference in New York City.

Hexaell Biotech Co., Ltd announced that the China National Medical Products Administration has cleared the IND, enabling the company to proceed a clinical trial for HepaCure, a novel device-drug combination product using hiHeps technology, a cell transdifferentiation technology which could directly convert human fibroblasts to hepatocyte like cells with liver cell functions.

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa® technology has powered important advances in ongoing clinical trials for the treatment of Alzheimer’s disease (AD).

Centene Corporation announced that it will host an investor day, including a question-and-answer session, on Friday, December 16, 2022.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage oncology company today announced preliminary results from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort evaluating adagrasib (400mg twice daily) concurrently combined with pembrolizumab in patients for the treatment of first-line NSCLC harboring a KRASG12C mutation across all PD-L1 subgroups.

SK Biopharmaceuticals, an innovative global pharmaceutical company, announced that it has received recognition from the Korean government as the company’s anti-seizure medication – cenobamate – exceeded $100 million in annual exports.

Ansys (NASDAQ: ANSS) today announced that GF has certified Ansys® RedHawk-SC™, Ansys® RaptorH™ and Ansys® HFSS™ semiconductor tools for its flagship 22FDX platform.